



EPFL researchers set out to create a labelfree method to study how drugs affect protein aggregation in neurodegenerative diseases. Conventional fluorescence and ThT assays could not reliably detect early aggregation states or mixed structural forms of αsynuclein, limiting insight into drug efficacy. The team needed a platform that combined high throughput screening with nanoscale structural precision.
Using the sciFLEXARRAYER S3, droplets of protein drug samples were printed into 48, 96, and 384 well plasmonic sensor chips. Each microwell contained gold nanorod arrays optimized for surface enhanced infrared absorption (SEIRA). The S3’s piezo driven, noncontact dispensing and fiducial control produced highly uniform ~450 pL spots without contamination, vital for infrared precision.
Deepthy Kavungal, Enzo Morro, et al, Advanced Science, 2025.